From 1 October 2022, MBS item 72814 for PD-L1 immunohistochemistry testing of tumour material from a patient diagnosed with non-small cell lung cancer, will be amended to also include testing of tumour material from a patient diagnosed with recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx.
The Medical Services Advisory Committee (MSAC) supported amending MBS item 72814 to include PD-L1 immunohistochemistry testing for patients with recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx to determine a patient's suitability for treatment with Pharmaceutical Benefits Scheme (PBS) listed pembrolizumab.
Further information can be found in the Factsheet below:
PDF Version Factsheet for amendment to pathology MBS item 72814 (PDF 165 KB)
Word Version Factsheet for amendment to pathology MBS item 72814 (Word 119 KB)